NASDAQ:IKT Inhibikase Therapeutics Q3 2025 Earnings Report $1.93 +0.02 (+1.05%) Closing price 06/29/2026 04:00 PM EasternExtended Trading$1.92 0.00 (-0.26%) As of 03:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Inhibikase Therapeutics EPS ResultsActual EPS-$0.13Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AInhibikase Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AInhibikase Therapeutics Announcement DetailsQuarterQ3 2025Date11/14/2025TimeAfter Market ClosesConference Call DateFriday, November 14, 2025Conference Call Time4:00PM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Inhibikase Therapeutics Earnings HeadlinesBank of America Securities Reaffirms Their Buy Rating on Inhibikase Therapeutics (IKT)June 29 at 12:30 PM | theglobeandmail.comAnalysts Set Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Price Target at $5.40June 25, 2026 | americanbankingnews.comBuy the “unseen winner of the AI race” before July 22Marc Chaikin - the analyst who called Nvidia before a 45,000% surge - says one overlooked AI stock could split into three separate companies in a rare event called a 'starburst' before July 22. Investors who buy shares before the announcement could automatically receive equal shares in each spinoff. A similar starburst at GE unlocked $184 billion for shareholders across three new companies.June 30 at 1:00 AM | Chaikin Analytics (Ad)LifeSci Capital Keeps Their Buy Rating on Inhibikase Therapeutics (IKT)May 17, 2026 | theglobeandmail.comAnalyst Flags High Risk in Inhibikase Therapeutics Stock, Urges Investors to Review 2025 Form 10-K Risk FactorsMay 14, 2026 | tipranks.comInhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent ActivityMay 12, 2026 | globenewswire.comSee More Inhibikase Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Inhibikase Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Inhibikase Therapeutics and other key companies, straight to your email. Email Address About Inhibikase TherapeuticsInhibikase Therapeutics (NASDAQ:IKT), a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.View Inhibikase Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Winnebago Misses Estimates, But Surges 14% After EarningsBlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings AloneTrip.com’s Selloff Raises a Bigger Question About Its Travel Recovery StoryFabrinet Is Becoming a Quiet Winner in the AI Optics BuildoutIs McCormick a Steal Ahead of Game-Changing Unilever Deal?New Stock Price Highs Are on the Menu for Darden RestaurantsMicron’s HBM Surge Could Redefine the AI Growth Story Upcoming Earnings PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026)Fastenal (7/14/2026)ASML (7/15/2026)Kinder Morgan (7/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
